Absolute and Relative Effectiveness of Cell- and Egg-based Quadrivalent Inactivated Influenza Vaccine Products from 2014-2015 to 2018-2019 seasons, U.S. Flu VE Network.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 41102880.
- Also identified by DOI 10.1093/cid/ciaf579 and PMC identifier 12667161.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Estimates of annual effectiveness of influenza vaccination combine multiple vaccine types. Reports of brand/product-specific vaccine effectiveness (VE) of egg- and cell-culture based quadrivalent inactivated influenza vaccines (IIV4/ccIIV4) are limited. Using an observational test-negative study design, we compared effectiveness of selected IIV4 and ccIIV4 products among outpatients enrolled in the US Flu VE Network from 2014-2015 to 2018-2019. We used multivariable logistic regression to estimate product- and age-group-specific absolute and relative effectiveness of recommended, age-appropriate vaccines against symptomatic laboratory-confirmed outpatient influenza. Relative effectiveness of ccIIV4 versus IIV4 products was estimated during two seasons from 2017-2019 among participants aged ≥4 years. Pooling data from five influenza seasons when 18% and 15% of vaccinated patients had received Fluarix® Quadrivalent or Fluzone® Quadrivalent IIV4, respectively, VE against influenza was 32% for Fluarix IIV4 and 37% for Fluzone IIV4. Pooling two seasons when 11% and 28% of vaccinated patients had received ccIIV4/Flucelvax® Quadrivalent and FluLaval® Quadrivalent IIV4, respectively, VE against influenza for each product was 30%. Absolute VE compared to unvaccinated patients was lowest against influenza A(H3N2) compared to that against A(H1N1)pdm09 and each B lineage; VE point estimates were lowest among patients aged ≥50 years compared to two younger age-groups. Relative effectiveness estimates were not statistically significant, indicating similar protection across vaccine products. Comparisons of influenza vaccine products over multiple seasons showed benefit against symptomatic laboratory-confirmed outpatient influenza of both egg- and cell culture-based quadrivalent inactivated influenza vaccines, with similar absolute and relative levels of protection provided by each product.